Provider Briefing: Aviane 28 Supply and Availability in 2026

If your patients are telling you they can't find Aviane 28 (Levonorgestrel 0.1 mg / Ethinyl Estradiol 0.02 mg) at their pharmacy, they're reflecting a real — if uneven — supply problem. While Aviane 28 is not currently on the FDA's formal drug shortage list, localized stock-outs have persisted since 2023 and continue to affect patient access in 2026.

This briefing covers the current state of Aviane 28 availability, the prescribing implications for your practice, therapeutic alternatives, and tools to help your patients find their medication.

Timeline: How We Got Here

Oral contraceptive supply disruptions aren't new, but they've intensified over the past several years:

• 2022-2023: Post-pandemic supply chain stress, combined with manufacturing consolidation in the generic oral contraceptive space, began causing intermittent shortages of several levonorgestrel/ethinyl estradiol formulations.
• 2023-2024: Several generic birth control brands experienced stock-outs at chain pharmacies. Patient complaints about availability increased sharply, particularly for low-dose formulations like Aviane 28 (0.1/0.02 mg).
• 2024-2025: Some improvement in manufacturing output, but "just-in-time" pharmacy inventory systems continued to leave patients without stock when demand spiked or deliveries were delayed.
• 2026 (current): Aviane 28 is not on the FDA shortage list, but availability remains inconsistent. Some pharmacies carry reliable stock; others report frequent back-orders, particularly in high-demand regions.

Prescribing Implications

The supply situation has several practical implications for prescribers:

Generic Substitution

Because Aviane 28 is itself a generic (of Alesse), pharmacists in most states can substitute any AB-rated generic without prescriber authorization — unless the prescription is written with "Dispense as Written" (DAW). Direct equivalents include Sronyx, Lutera, Orsythia, Larissia, Aubra, Falmina, and Lessina, all containing Levonorgestrel 0.1 mg / Ethinyl Estradiol 0.02 mg.

If you're writing prescriptions for Aviane 28, consider prescribing by generic name (levonorgestrel/ethinyl estradiol 0.1 mg/0.02 mg) without brand specification. This gives pharmacists maximum flexibility to fill with whatever equivalent is in stock.

Therapeutic Alternatives

When no 0.1/0.02 formulation is available, the following are reasonable therapeutic alternatives within the same drug class:

• Levonorgestrel 0.15 mg / Ethinyl Estradiol 0.03 mg (Levora, Altavera, Marlissa) — slightly higher doses of both hormones, well-studied, widely available.
• Norgestimate 0.25 mg / Ethinyl Estradiol 0.035 mg (Sprintec, Mono-Linyah) — different progestin, also FDA-approved for acne, one of the most widely available OCs.
• Norethindrone 1 mg / Ethinyl Estradiol 0.02 mg (Junel 1/20, Larin 1/20) — different progestin, same low estrogen dose.

Switching within the combined OC class generally does not require a washout period. Patients should be counseled to use backup contraception for 7 days if switching to a formulation with a different progestin.

Patient Counseling Points

When addressing supply concerns with patients:

• Reassure them that generic substitution with the same formulation is clinically equivalent — the active ingredients and doses are identical.
• Discuss the option of prescribing by generic name for maximum pharmacy flexibility.
• Recommend they refill 5-7 days early to build in buffer time.
• Suggest using stock-checking tools like Medfinder for Providers to help locate available inventory.

Current Availability Picture

Based on available data and patient reports:

• Chain pharmacies (CVS, Walgreens, Rite Aid): Availability varies by location. Urban areas with high patient volume tend to experience more frequent stock-outs.
• Independent pharmacies: Often more reliable for specific generics due to access to different wholesale distributors.
• Mail-order pharmacies: Generally have better access to consistent supply, though delivery timelines may not work for patients who've already run out.
• Grocery/warehouse pharmacies (Costco, Kroger, H-E-B): May have stock when retail chains don't, due to separate supply agreements.

Cost and Access Considerations

Under the ACA contraceptive coverage mandate, most insured patients should receive oral contraceptives at $0 copay. However, several scenarios can create cost barriers:

• Non-formulary substitutions: If a patient's plan covers Sronyx but not Aviane, and the pharmacy dispenses Aviane, the patient may face a copay. Prescribing by generic name helps avoid this.
• Uninsured patients: Cash prices range from $40 to $70 per pack at retail. Discount cards (GoodRx, SingleCare) can reduce this to $15-$25.
• Patient assistance: The Teva Cares Foundation provides certain Teva medications at no cost to eligible uninsured patients. Information at tevacares.org.

For patient-facing cost information, direct patients to our guide on saving money on Aviane 28.

Tools and Resources for Your Practice

Several tools can help your practice manage the supply situation:

• Medfinder for Providers: Real-time pharmacy stock search. Your staff can check availability before sending a patient to a specific pharmacy.
• FDA Drug Shortage Database: Monitor official shortage listings at accessdata.fda.gov.
• ASHP Drug Shortage Resource Center: Additional supply chain intelligence from the American Society of Health-System Pharmacists.
• Prescribe generically: Writing for "levonorgestrel/ethinyl estradiol 0.1/0.02" rather than "Aviane" gives pharmacists the widest latitude to fill.

Looking Ahead

Several trends may improve the supply picture over the next 12-18 months:

• Additional generic manufacturers entering the levonorgestrel/EE market
• FDA initiatives to streamline generic drug approvals for medications with supply concerns
• Telehealth expansion making it easier for patients to get prescriptions adjusted quickly
• Growing adoption of real-time pharmacy stock tools like Medfinder

However, the structural factors driving supply variability — manufacturing consolidation, global raw material sourcing, and just-in-time pharmacy inventory — are unlikely to resolve quickly. Prescribers should continue to prepare patients for the possibility of occasional stock-outs.

Final Thoughts

The Aviane 28 supply situation in 2026 is manageable but requires proactive prescribing and patient communication. By prescribing generically, discussing alternatives in advance, and directing patients to tools like Medfinder, you can minimize the impact of supply disruptions on your patients' contraceptive care.

For the patient-facing version of this update, share our article on the Aviane 28 shortage update for patients. For a practical guide to helping patients find stock, see our provider's guide to helping patients find Aviane 28.